Cargando…
SUN-357 Trial in Progress: A Multicenter, Dose-titration, Open-Label Phase 2b Study of Nevanimibe Hydrochloride, a Novel ACAT1 Inhibitor, for the Treatment of Classic Congenital Adrenal Hyperplasia
More than 90% of classic congenital adrenal hyperplasia (CAH) patients have defects in the cytochrome P450 enzyme steroid 21-hydroxylase, resulting in the inability to produce cortisol as well as the overproduction of androgens and androgen precursors such as 17-hydroxyprogesterone (17-OHP). Managem...
Autores principales: | Lin, Vivian, Ijzerman, M. Marian, Plaunt, Marianne, Mohideen, Pharis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552740/ http://dx.doi.org/10.1210/js.2019-SUN-357 |
Ejemplares similares
-
SUN-167 Treatment Considerations for a Healthy Pregnancy in Women with Classical Congenital Adrenal Hyperplasia (CAH)
por: Calzia, Megan, et al.
Publicado: (2020) -
SUN-374 Management of Congenital Adrenal Hyperplasia in Pregnancy with Female Fetus
por: Kothari, Vallari, et al.
Publicado: (2019) -
SUN-354 Quality of Life in Patients with Primary Macronodular Adrenal Hyperplasia
por: Charchar, Helaine, et al.
Publicado: (2019) -
SUN-361 Reproductive Outcomes in Females with Virilizing Forms of Congenital Adrenal Hyperplasia
por: Falcao, Camila, et al.
Publicado: (2019) -
SUN-174 Giant Bilateral Myelolipomas in a Patient with Congenital Adrenal Hyperplasia
por: Duro, Teodor, et al.
Publicado: (2020)